Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Officer of Helomics

World News: . []

MINNEAPOLIS, June 12, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: AIPT) (“Predictive Oncology” or the “Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has appointed Amelia Warner, Pharm.D., RPh, as the interim chief operating officer for its Helomics division.

Dr. Carl Schwartz, Predictive Oncology’s Chief Executive Officer, commented, “Dr. Warner brings over 15 years of experience building businesses in the space of personalized medicine to her new role as interim chief operating officer for Helomics.  Her outstanding accomplishments in the fields of pharmacogenomics and building biorepository programs with Children's Hospital of Philadelphia, Schering-Plough, and Merck throughout her storied career establish her as a highly valued member of our growing team.  Her demonstrated leadership optimizing genetic sample collection, data generation, data transfer and establishing international policy for both genetic specimens and human specimen research will serve Predictive Oncology’s goals of bringing new opportunities for drug discovery and advancing precision medicine.  We are excited about her ability to bring our virtual AI drug discovery program to big pharma with her intimate understanding of both the landscape and market needs.  Her role on the company’s Advisory Board has been highly productive and influential as we pursue our AI-driven approach to personalized medicine.  Her understanding of the immense value of our tumor response data and how to leverage it into pharma drug discovery programs is incomparable and we are excited to move forward with her stewardship in this senior management role.”

Prior to joining Helomics, Dr. Warner founded Global Specimen Solutions, Inc. (GSS) in 2013, which radically improved translational science through powerful new pipeline data management analytics for global specimen data tracking for the pharmaceutical industry.  After rapid market uptake and growth, GSS was sold to a public company in December 2017.  Prior to GSS, Dr. Warner served as CEO for Gentris Corporation, where she led a financial and operational turnaround resulting in the successful sale of Gentris to a public company.  She has also served as head of Clinical Pharmacogenomics and Clinical Specimen Management for Merck Research Laboratories (MRL).  In this role, she led a data overhaul for the Clinical Translational Medicine program, oversaw all clinical pharmacogenomics projects, as well as policies and procedures for biosample collection and storage for clinical trials samples. In addition, she has served as chair of the Industry Pharmacogenomics Working Group (I-PWG) and was a PhRMA representative to ICH E16- Genomic Biomarkers Related to Drug Response.

Dr. Warner completed both a residency in pediatric pharmacotherapy and a fellowship in clinical pharmacology/pharmacogenomics at St. Jude Children’s Research Hospital.  She holds a BS in biology from Wake Forest University and a Pharm.D. from the University of North Carolina at Chapel Hill.

“Multiple firms, whether CRO or drug discovery platforms, claim to have comprehensive data and an AI component, but Helomics’ unique, clinically validated, cell-based patient derived tumor testing technology coupled with its massive database of both in vitro drug response profiles paired with clinical outcome data will provide its clients with intelligent designed AI powered multi-omic predictive models of tumor drug response and drive our goal of revolutionizing patient care - a distinct technological advantage, that has yet to be fully recognized in the market,” added Dr. Warner.  “I look forward to collaborating with both management and implementation teams at Helomics to deliver superior results for our clients, and enhanced valuation for shareholders of Predictive Oncology.”

“Dr. Warner brings world-class clinical pharmacogenomics expertise and vast clinical research organization experience to her new role as interim chief operating officer of Helomics, after having served as an integral member of the company’s Advisory Board since mid-2017.  Our strong history of successes working together at Gentris yielded tremendous outcomes, where we were able to increase productivity and significantly enhance valuation.  Amelia’s new role will capitalize on her broad background as we proceed in commercializing and monetizing our AI platform and capabilities.  Amelia’s background and capabilities will serve these goals to drive the realization of Helomics’ vast potential,” commented Gerald Vardzel, president of Helomics.

MediaJules AbrahamCORE IR917-885-7378

More news and information about Predictive Oncology Inc.

Published By:

Globe Newswire: 13:00 GMT Wednesday 12th June 2019

Published: .

Search for other references to "predictive" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us